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Abstract: More than 6 000 drug users die of 
overdose each year in the European Union, and 
most of these deaths occur among problem drug 
users and involve opioids. In addition, many 
deaths related indirectly to drug use occur each 
year. To gain a clearer picture of the overall 
number of lives lost due to drug use in Europe, 
this paper builds on the results of an earlier work 
that looked at all-cause mortality among problem 
drug users. By linking data on entrants to drug 
treatment programmes with information from 
death registries, mortality cohort studies can 
determine death rates from all causes within the 
study population. The study presents data from 
nine European countries, including seven not 
previously studied using EMCDDA methodology. 
Among over 31 000 participants (22 % female), 
covering 203 000 person-years of follow-up, 
2 886 deaths were recorded, 18 % among 
females. Overall crude mortality rate per 1 000 
person-years follow-up was 14.2, but varied 
geographically from 3.5 to 22.7. Cause of death 
was reported in 71 % of all deaths, half of which 
was accounted for by external causes: overdose 
(35 %), suicide (5 %) and other external causes 
(10 %). Somatic causes accounted for about 45 % 
of the known-cause deaths: HIV/AIDS (14 %), 
circulatory diseases (9 %), respiratory diseases 
(5 %) and other somatic causes (16 %). Risk of 
death among problem drug users was typically 10 
or more times that among their peers in the 
general population. The analysis shows that the 
deaths of problem drug users are overwhelmingly 
premature and preventable.
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illicit drug use is found among these opioid users, particularly 
those injecting.
Overall mortality among problem drug users is studied 
primarily by following cohorts of problem drug users over time. 
Cohort studies capture all deaths among the participants 
regardless of their supposed relation to drug use, of their 
cause, and of the practices of coding the cause of death in 
mortality registries. This approach identifies the whole 
spectrum and intensity of deaths, and can reveal the risks to 
life associated with long-term drug use. 
Beyond overdoses, mortality related to drug use is a complex 
phenomenon, with a number of dimensions that require 
different data sources and methodology, such as cohort 
studies, to help explain them. 
I Objectives and content
The first aim of this paper is to present the most up-to-date 
picture given by cohort studies of the overall mortality 
among opioid drug users in Europe, and to ascertain and 
quantify the various causes. Secondly, the paper seeks to 
identify, where data are available, changes over time and 
differences between countries. The third aim of the paper is 
to identify areas where further data and research are 
necessary in order to inform policymaking and prevent these 
avoidable deaths. 
The remainder of this publication consists of three sections. In 
the first of these sections, key findings from recent mortality 
studies in Europe are presented. The second section presents 
the result of a pooled study involving cohorts in nine European 
countries. The final section looks at the public health 
implications of the findings of cohort studies.
Information on risk and protective factors and on the options 
available for prevention and other interventions are not covered 
by this publication. Updated documents on prevention of 
overdose are referred to though and briefly discussed.
I Introduction
The prevalence of illicit drug use in Europe and the number of 
deaths related to drug use remain high by historical standards. 
Illicit drug overdoses are responsible for a considerable share 
of premature and avoidable mortality among young adults, 
accounting for an estimated 4 % of all deaths among those 
aged 15–39 in Europe (EMCDDA, 2013d). In some countries, 
the proportion is much higher: 21 % in Estonia, 14 % in 
Norway, 12 % in Ireland, 11 % in Finland and 10 % in the 
United Kingdom. Many of these deaths are related to injecting 
drug use and, in most cases, involve a combination of 
substances (Best et al., 2000; EMCDDA, 2013c). From 1990 
to 2012, between 6 100 and 8 500 overdose deaths were 
reported each year in Europe. Despite major increases in the 
provision of drug treatment in Europe, the overall number of 
reported overdose deaths increased between 2003 and 2008, 
although it has since fallen back to an estimated 6 100 
overdose deaths per year in 2012.
Overdoses, however, represent only part of the mortality 
related to drug use. In Europe, overdoses were estimated to 
account for roughly one-third to half of deaths among 
problem drug users (EMCDDA, 2011). A substantial number 
of deaths among problem drug users are indirectly related to 
drug use. Among these are deaths due to HIV/AIDS acquired 
through injecting drug use, deaths due to other blood-borne 
infections, traffic accidents and other accidents, violence 
and suicides. Also contributing to some of the non-overdose 
deaths among drug users are the health and social problems 
associated with problem drug use, such as social exclusion, 
homelessness, chaotic lifestyles, concomitant mental health 
problems, or concomitant excessive use of alcohol or 
tobacco. 
The high levels of mortality among drug users are a cause for 
concern both at the individual and the societal level. The 
number of problem opioid users (those injecting opioids or 
using the drug regularly or over a long time) in Europe is 
cautiously estimated at about 1.3 million (EMCDDA, 2014), 
and the greatest share of morbidity and mortality related to 
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the pooled study allows analysis of sub-groups like women or 
people who died from specific causes such as suicide or 
disease related to hepatitis C virus infection.
European multisite cohort studies
The present European multisite study was conducted in 
2012–13 and covers nine countries. The latest multisite study 
is similar in approach to the COSMO study, the first European 
multisite study coordinated by the EMCDDA (Bargagli et al., 
2006a; Bird, 2010). Some links and comparisons can be made 
between the two exercises. 
The present study: recruitment settings and methods
The impetus for the present cohort study springs from the 
data collection for the 2011 Selected Issue, when a number of 
countries reported summaries of the findings of cohort 
studies (EMCDDA, 2011; Giraudon et al., 2012). The EMCDDA 
decided to conduct a pooled analysis of different national 
datasets in order to gain better insights into mortality among 
problem drug users. Key issues to be addressed included 
trends in mortality, comparison of mortality between countries 
and, in order to analyse cause-specific mortality, a gain in 
statistical power.
The study population was made up of cohorts of opioid users 
enrolled in treatment (mainly opioid substitution treatment), 
collated by the EMCDDA national experts on drug-related 
deaths. Datasets shared between experts and the EMCDDA 
were fully anonymised, and any information that would 
compromise the anonymity of the participants or breach the 
national regulations was deleted from the datasets before 
they were shared. The format of a minimum dataset had 
been recommended to all contributing experts, following the 
EMCDDA cohort protocol (see box on the EMCDDA cohort 
protocol). The core dataset included age, gender and primary 
drug, date and cause of death if the person had died, and the 
dates necessary to compute the length of time followed up 
(date of enrolment and end of follow-up, whether for end of 
study, loss to follow-up or death). Information on cause of 
death was available for all cohorts except for those from 
Amsterdam and Poland. The different data analyses were 
conducted with SPSS and Stata. Several data analysis 
workshops were conducted in the course of the study. 
I Methods and data sources
The data sources and methods used are presented in the 
sections below. Further information on cohort studies is given 
in text boxes. 
I Mortality cohort studies in Europe
The overview of mortality cohort studies among drug users in 
Europe is based on a 2011 EMCDDA Selected Issue. The main 
European mortality studies that were analysed for the 
Selected Issue were outlined in an appendix. The studies were 
selected primarily to cover as many countries as possible, and 
according to the size of the population followed up. Recent 
long-term follow-up studies conducted at national level and 
enrolling between 3 000 and 5 000 participants were available 
for Croatia, Germany, Latvia, Norway, Poland, Slovenia and 
Sweden. While many of these studies have been published, 
some countries provided cohort data that are as yet 
unpublished. The participants in the cohort studies analysed 
were predominantly problem drug users, most of whom were 
engaged in opioid substitution treatment or some other form 
of treatment for opioid dependence at the time of their 
enrolment. Studies conducted in other settings, such as 
juvenile correctional institutions, are available for some 
countries.
This publication supplements the Selected Issue with an 
updated review of the papers on mortality published in Europe 
since 2011, and by a review of recent national reports (2011 
data, reported in 2012) to the EMCDDA. In 2012, seven 
national reports included information on cohort studies: 
Cyprus, the Czech Republic, Lithuania, Luxembourg, Norway, 
Slovenia and the United Kingdom, although not all of these 
provided results of recent studies.
I Multisite pooled cohort study
Rationale and added value of pooling European studies
For the present paper, cohort studies carried out in nine 
European countries have been analysed together. The 
rationale for conducting a pooled analysis was to improve the 
statistical power of cohorts, which on their own are often 
limited to a few thousand participants enrolled. In particular, 
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The information analysed in this paper is mainly derived 
from longitudinal follow-up studies of groups — ‘cohorts’ 
— of problem drug users, which systematically identify the 
causes of all deaths among the cohort. Cohort studies may 
be classified by whether they use an active or passive 
follow-up. Active follow-up studies (e.g. by periodical 
interviews) allow researchers to measure behaviour over 
time, for example the duration of treatment over the years, 
or whether the person has changed his or her primary drug. 
Passive follow-up methods link records between lists of 
drug users and mortality registries, but cannot collect 
information on the subsequent drug-use or drug-treatment 
history of the participant after enrolment in the study. 
Mortality cohort studies among problem drug users can 
determine overall and cause-specific mortality rates and can 
estimate the excess mortality of drug users, compared with 
their peers in the general population. Cohort studies also 
detect changing patterns in the causes of death (Darke et al., 
2007). Large-scale cohort studies can also help to determine 
the impact of interventions. For example, cohort studies 
provide insight into the trends of HIV/AIDS-related mortality 
among injecting drug users, which decreased dramatically 
after the introduction of effective HIV treatment.
Findings from cohort studies can be used to produce 
national estimates of deaths among all problem drug users. 
For that, mortality rates can be extrapolated from cohort 
studies to local or national estimates of the number of 
problem drug users (Cruts et al., 2008). Another approach 
that can be used to estimate the number of deaths due to 
drug use is to derive drug-attributable fractions from 
mortality cohort studies and apply these fractions to the 
causes of death that are most frequently related to drug use 
(e.g. HIV/AIDS, accidents, suicide and poisonings) and 
which are recorded in the general population mortality 
registries. Findings from cohort studies can also contribute 
to the validation of data from other sources, for example, 
the number of drug-induced deaths reported in mortality 
registries. 
Cohort studies have both strengths and limitations when 
used for the study of mortality among drug users. The 
capacity to provide information on mortality from all causes 
among drug users, beyond drug-induced deaths, is the 
main advantage of mortality cohort studies. Their main 
limitation is that they may underestimate the number of 
deaths when some subjects are lost to follow-up. In 
addition, the results may not be readily generalised to other 
populations of drug users.
Finally, comparability between studies can be compromised 
by differences in recruitment settings (e.g. treatment 
centres, outreach services, needle exchange services), 
populations of drug users enrolled (e.g. cocaine users, 
arrestees) and study design (e.g. enrolment of current drug 
users, retrospective studies of persons treated some years 
ago) (Degenhardt et al., 2011a).
In addition to mortality cohorts, other follow-up studies, 
with different primary objectives or recruitment criteria can 
also be used to monitor mortality. Examples include the 
VEdeTTE studies in Italy (Bargagli et al., 2006b; Vigna-
Taglianti et al., 2007), the primary objective of which was to 
assess treatment outcome, studies among those arrested 
for drug law offences in France (Lopez et al., 2004), and 
studies of injectors with hepatitis in the Czech Republic 
(Lejckova and Mravcik, 2005, 2007). 
What are cohort studies and what do they tell us?
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mortality ratios (SMRs) were examined by country, age and 
sex. SMRs were calculated from the expected numbers of 
deaths in the European population (27 EU Member States) in 
2006, using data extracted from Eurostat. These 
computations were done separately for the overall mortality 
and the cause-specific mortality.
Nine cohorts were included in the pooled analysis. These 
studies covered either national or city populations (Figure 1). 
All cohorts consisted of opioid users who entered treatment 
during the period 1995–2011. The data were linked to national 
registers of all deaths (or the municipal register in the case of 
Amsterdam). Crude mortality rates (CMRs) and standardised 
To assist European countries in carrying out useful and 
harmonised studies, the EMCDDA together with national 
experts produced a protocol on conducting and analysing 
mortality cohort studies (EMCDDA, 2012). The protocol 
recommends the use of treatment centres as the setting 
for recruitment of patients into cohort studies. Treatment 
centres are usually able to recruit a relatively 
representative sample of problem drug users in treatment, 
typically, opioid users. Treatment centres are also an 
appropriate setting for the collection of personal identifiers 
needed to trace the participants in mortality registries. 
There are, however, limitations associated with recruiting 
drug users in these settings, as the findings are not 
necessarily transposable to other drug users, particularly 
those not in treatment. To facilitate comparison across 
studies, the EMCDDA also recommends the use of 
prospective studies that focus on current drug users: 
participants are enrolled on entry to drug treatment and 
the study looks at mortality over the following months or 
years. Some studies are retrospective, that is to say the 
individuals have been enrolled in the past, at the moment 
of intake to treatment. However, in these studies, there 
might be gaps, errors and non-standard data, which will be 
difficult or impossible to complete or correct. The EMCDDA 
stresses the necessity of confidentiality and protection of 
identifiable personal data. Ethical approval and 
participants’ consent are needed, as is compliance with 
national regulations and laws. 
The COSMO study was the first European multisite cohort 
study to be coordinated by the EMCDDA. In common with 
the current pooled analysis, it required agreement on a 
common core dataset and involved a number of data 
analysis workshops. The study population was made up of 
cohorts of opioid users who entered treatment during the 
period 1990–99. Deaths among the subjects were traced 
back by linking the cohorts with national or municipal 
registers. Eight European sites were included in the COSMO 
Study: Spain (Barcelona), Portugal (Lisbon), Italy (Rome), 
Denmark, Ireland, United Kingdom (London), the Netherlands 
(Amsterdam) and Austria (Vienna). The sites were all in 
countries that joined the European Union before 2004.
The pooled analysis includes cohorts from seven countries 
that were not involved in the COSMO study (Croatia, Latvia, 
Malta, Norway, Poland, Romania and Slovenia), and the 
majority of which are in the eastern half of the European 
Union. The cohorts in the Netherlands (Amsterdam) and 
Spain (Barcelona) were involved in the COSMO study. The 
follow-up of the cohort in the Netherlands has been 
extended to 2009 for this analysis, which adds seven years 
of follow-up compared with COSMO. The cohort in 
Barcelona has also been updated (recruitment from 1997 to 
2007 for this exercise, compared with 1999 to 2001 for the 
COSMO analysis). 
The current exercise provides an insight into mortality 
among drug users in a time when effective HIV treatments 
were readily available to this group, which was not the case 
in the 1990s when the COSMO studies were carried out. 
The lack of effective HIV treatment in the 1990s was 
reflected in the many deaths among drug users accounted 
for by HIV/AIDS. This was particularly the case in Portugal, 
Italy and Spain, where the prevalence of HIV infection 
among drug users was high.
EMCDDA cohort protocol
The COSMO study and its successor
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users is roughly 10 to 20 times that of the general population of 
the same age and gender (EMCDDA, 2011). Excess mortality 
risk is usually higher in females than in males, largely due to 
lower mortality rates among women in the general population. 
In addition, excess mortality risk is usually higher in younger 
drug users than in older ones, again largely due to lower 
mortality rates among their peers in the general population.
For problem drug users, the excess risk of death from certain 
causes is particularly high; chief among these are overdose, 
suicide, end-stage liver disease due to hepatitis C virus 
infection and heavy alcohol use, and violence. Again, mortality 
rates due to these causes are usually much lower in the 
general population. 
Most common causes of death among  
problem drug users
Four broad categories of causes of death among problem drug 
users have been identified in the literature, namely overdose, 
disease, suicide and trauma (Darke et al., 2007). Among 
diseases, conditions related to blood-borne viruses (HIV, 
hepatitis B and hepatitis C viruses), neoplasms, other liver 
diseases, and diseases of the respiratory and circulatory 
systems can be associated with drug use. Trauma refers to 
serious or critical wounds or bodily injuries such as from 
accidents (traffic accidents, falls, drowning) and violence, and 
also includes assault and homicide. 
Among problem drug users, in particular, cause of death may 
not be clear-cut. Those with severe drug problems, especially 
opioid users, comprise a very vulnerable population. Often, 
they have additional problems such as psychiatric co-
morbidity, social exclusion, difficulties in accessing services, 
alcohol use and dependence, all of which can cause 
considerable harm in their own right. 
Results from the studies presented in the Selected Issue, 
which are also supported by results from other reports, show 
that while there can be great variation between studies, a 
rough generalisation can be made that between one-third and 
half of deaths among problem drug users are due to overdose, 
and between one-fifth and two-fifths are due to suicide and 
trauma (Best et al., 2000; Darke et al., 2007; Degenhardt et al., 
2011a; EMCDDA, 2011; Giraudon et al., 2012). Less than 
one-tenth of the deaths recorded in recent cohort studies are 
attributed to HIV/AIDS. A substantial proportion of drug users 
die from ‘other causes’, which appears mainly to include 
somatic and chronic conditions such as liver diseases, 
cardio-vascular and pulmonary conditions, cancer and 
infections other than HIV. In the studies cited in the Selected 
Issue, ‘other causes’ typically accounted for about one-quarter 
of all deaths, although this category can represent up to half of 
the recorded deaths in some cohorts. 
I  Key findings from recent mortality  cohorts in Europe
I A review of cohort studies in Europe
This brief review of cohort studies in Europe comprises three 
parts. First, some of the key findings of the 2011 Selected 
Issue are presented. Of particular interest are the mortality 
rates and excess risk of mortality among participants in 
cohort studies compared with the general population, and 
the most common causes of death. Secondly, an update is 
presented, based on the data reported in the 2012 Reitox 
national reports (2011 data). Finally, the findings of a 
selection of published papers on cohort studies among drug 
users are presented. The papers cited include large 
international reviews and national studies carried out in 
European countries. 
Mortality rates and excess mortality in cohorts of 
problem drug users
Cohort studies point to an excess risk of mortality for problem 
drug users compared with their peers of the same age and 
gender in the general population. Overall, the mortality for drug 
FIGURE 1
Countries and cities participating in the 2012–13 pooled 
analysis and the COSMO study, showing number of person-
years for each pooled analysis site (circles) and location of 
COSMO sites (stars)
Lisbon
Ireland
London
Malta
Amsterdam
Norway
Bucharest
Latvia
Poland
Rome
Zagreb
Slovenia
Barcelona
Vienna
Denmark
45 871 
21 789  
13 564 
19 479   
24 506  
21 783  
19 427  
25 775 
10 919  
NB: 2012–13 pooled analysis sites: Amsterdam (Netherlands), Barcelona 
(Spain), Latvia, Malta, Norway, Poland, Romania (Bucharest), Slovenia, Zagreb 
(Croatia). COSMO sites: Amsterdam (Netherlands), Barcelona (Spain), Denmark, 
Ireland, Lisbon (Portugal), London (United Kingdom), Rome (Italy), Vienna 
(Austria).
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substitution treatment were due to somatic causes and 
injuries. It is generally accepted that the annual mortality rate 
among untreated injecting heroin users in Norway is in the 
range of 2–4 %. 
In a study of Norwegian substitution treatment clients for the 
period 1997–2003, an annual mortality rate of 2.4 % was 
found prior to treatment and 3.5 % post-treatment among 
those who terminated substitution treatment. In the same 
study, the annual mortality rate was 1.4 % for those receiving 
substitution treatment, among whom the main causes of 
death were somatic causes (55 %), overdose (27 %) and 
trauma (18 %). However, for the observed times prior to and 
after substitution treatment, overdoses dominated as the 
main cause of death (Clausen et al., 2008, 2009). The annual 
mortality rate for substitution treatment clients has gradually 
decreased in Norway since 2002, from an estimated 15 per 
1 000 to a current rate of 8 per 1 000 (1). 
Other recently published cohort studies
To supplement the short review of the 2012 national reports, 
some recently published papers of interest are mentioned 
below. This selection of reviews and original papers on 
European cohorts is not intended as a comprehensive 
literature review. Some recent findings published on deaths 
related to stimulants are also presented (see boxes on 
mortality among cocaine users and among amphetamines 
users).
A Scottish study on premature mortality among injecting drug 
users used a ‘life-course data’ approach to collect 
retrospective data on family life, employment and health. It 
found that early life adversity was apparent for many cases, 
with a steady progression into early criminal behaviour and 
drug misuse. It suggested that more qualitative studies are 
needed to highlight areas which might require early 
intervention (Copeland et al., 2012). 
Also in Scotland, a large linkage study was conducted on 
patients in contact with drug treatment services between 
1996 and 2006. The overall SMR fell over time from 6.4 (95 % 
CI, confidence interval, 6.0–6.9) in 1996–2001 to 4.8 (95 % CI 
4.6–5.0) in 2001–06. More than half of the deaths were due to 
overdose. Alcohol misuse increased the risk of overdose, 
suicide and deaths from digestive system diseases. The 
authors concluded that individuals diagnosed with hepatitis C 
virus infection are particularly vulnerable and may need 
additional support (Merrall et al., 2012).
In Norway, a linkage study with a 33-year follow-up period 
was conducted among anti-HCV-positive injecting drug users 
(1)  The data included in the multisite pooled study are from 1997 to 2003 only.
Mortality cohort studies reported in the 2012 Reitox 
national reports
Five of the 30 national focal points reporting to the EMCDDA 
presented new developments or data from cohort studies in 
their 2012 national reports. 
For the Czech Republic, results of a number of studies were 
presented in the Selected Issue (EMCDDA, 2011; Lejckova 
and Mravcik, 2005, 2007; Zábranský et al., 2011). Mortality 
rates for patients in substitution treatment were relatively low, 
ranging from 3.5 to 7.2 deaths per 1 000 person-years, similar 
to the mortality rates estimated in other countries in central or 
eastern Europe (see below). The mortality rate among clients 
enrolled in the substitution treatment register was estimated 
at 1.7 per 1 000 (Reitox National Report, 2012); this, however, 
is an underestimate, as deaths are recorded as a reason for 
terminating treatment, rather than traced through systematic 
linkage with the mortality register. Some deaths are probably 
not reported to the study by physicians and are therefore not 
counted.
A recent study among a cohort of very young injectors, whose 
principal drug was methamphetamine or heroin, found that 
mortality was high in males (4.8 deaths per 1 000 person-
years overall), in particular in the first three years after 
enrolment and due to external causes exclusively (overdose 
and accidents) (Zábranský et al., 2011).
In Lithuania, data from the State Mental Health Centre 
suggested a mortality rate of 8.4 deaths per 1 000 patients 
dependent on drugs and psychotropic substances registered 
in 2011 (42 out of 5 935 drug users). As there was no 
systematic linkage of the treatment register with the general 
mortality register, the mortality rate may be an underestimate. 
Three-quarters of the reported deaths were among opioid 
users (33/42). The proportion of patients who were opioid 
users or users of other drugs is not reported. The mean age of 
death has increased over the years and reached 42.5 years in 
2011. The cause of death was known for only half of the cases. 
Of those, about half died of external causes and the remainder 
died of somatic causes. 
In Slovakia, a retrospective cohort study among drug 
treatment clients in Bratislava found the highest mortality 
rates among those dependent on sedatives (25 deaths per 
1 000 person-years), followed by those dependent on opioids 
(7.3 deaths per 1 000 person-years). 
In Norway, 54 deaths from various causes were reported 
during 2011 among clients registered in the opioid 
substitution programme. There were 6 640 clients enrolled in 
the programme at the end of 2011, indicating a total mortality 
rate of about 8 per 1 000 person-years among those in 
substitution treatment. The majority of deaths among those in 
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infection, mortality rates among HCV RNA-positive 
individuals were not different to those among HCV RNA-
negative individuals. However, among injecting drug users 
with chronic HCV infection who have survived until 50 years 
of age, HCV infection emerges as the main cause of death 
(Kielland et al., 2013a).
Most published papers on mortality among drug users focus 
on opioid users but there is a growing literature on mortality 
and morbidity related to cocaine use (see box). 
admitted to residential drug treatment in 1970–84. The 
study found that, among this group of drug users, who had 
been exposed to the virus at some point in their lives, the 
all-cause mortality rate was 18 per 1 000 person-years. The 
main cause of death was overdose (45 %), followed by 
suicide (9 %) and accidents (8 %). Among those testing 
positive for HCV RNA, which is taken to indicate an active 
infection, liver disease was the cause in 7.5 % of deaths. The 
authors concluded that overall mortality is high among the 
study group and that, in the first three decades after HCV 
In recent years, cocaine has been detected in an increasing 
number of drug-induced deaths and drug-related 
emergencies reported in European countries (Corkery, 
2012; EMCDDA, 2013c). The available data do not permit a 
clear picture of trends in cocaine-related deaths in Europe 
as a whole. For Spain and the United Kingdom, the 
countries with the highest rates of cocaine use in the 
general population, an increase was observed before 2008, 
but the most recent data suggest the numbers have since 
decreased. The same trend was observed for emergencies 
related to acute cocaine intoxications (EMCDDA, 2013b; 
Mena et al., 2013). 
Cocaine is very rarely identified as the only substance 
contributing to a drug-induced death (Corkery, 2012), and 
long-term use causes complex and interlinked harms 
(Dinis-Oliveira et al., 2012).
A recent review on mortality among cocaine users 
(Degenhardt et al., 2011b) included nine studies in Brazil, 
Canada, the United States and three European countries 
(France, Italy, Netherlands). Crude mortality rates ranged 
from 0.54 to 4.6 per 100 person-years. The main causes of 
mortality, where known (Brazil, Canada, Italy, United States), 
included fatal gunshots (Brazil), overdose, HIV/AIDS, trauma 
and infections related to injecting, vascular diseases and 
suicide. The authors concluded that there are limited data 
available on the extent of elevated mortality among 
problematic or dependent cocaine users, and that it is 
unclear how generalisable the results may be to other 
populations. 
A recent Danish cohort study, among individuals in treatment 
for cocaine use, showed an excess mortality risk of 6.4 
compared with peers of the same age and sex in the general 
population (Arendt et al., 2010). Dependent cocaine users 
show high rates of attempted suicide. Suicide attempts 
among cocaine users are not restricted to those who inject 
the drug: a study in Australia showed that 10 % of cocaine 
users who had never injected a drug also had this history 
(Darke and Kaye, 2004). More recently, in Spain, a cohort 
study found that short-term mortality in a sample of young 
Spanish primary cocaine users was five times (4.7; 95 % CI 
2.4–9.0) that of their peers in the general population. The 
authors hypothesised that the excess mortality may largely 
be explained by a history of opioid use or the risk of starting 
such use. Although differences between subgroups did not 
reach statistical significance, mortality appeared to be lower 
among those who had never used opioids compared with 
those who had used opioids at some time in their life. 
Similarly, mortality appeared to be lower among those who at 
baseline neither used opioids, nor injected nor smoked 
cocaine compared with those reporting any of these risk 
behaviours at baseline (Barrio et al., 2013). 
Mortality among cocaine users
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I Results of the multisite pooled study
Patients enrolled
A total of 31 218 people were enrolled in the pooled cohort, 
with follow-up amounting to 202 947 person-years. Females 
made up 22 % of the subjects and accounted for 21 % of the 
person-years followed up. The mean age at enrolment was 
28.6 years (28.7 for males and 28.2 for females), but this 
varied across countries. For both genders, the age-band 
25–29 accounted for the largest number of person-years 
followed up (Figure 2). 
The gender distribution varied across countries from 68 % 
males in Norway to 84 % in Slovenia, but in most of the 
countries around 80 % of the participants were males  
(Table 1). 
The age distribution also varied across the different study 
sites, with Amsterdam, Norway and Barcelona having the 
oldest participants at the time of enrolment, whereas in 
Bucharest and Malta, more than two-thirds of the 
participants were younger than 25 at the time of enrolment 
(Table 1; Figure 3).
FIGURE 2
Distribution of person-years followed up in the nine sites, by 
age-band and gender
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There are growing concerns in Europe about the prevalence of 
use and harms related to amphetamines, including 
methamphetamine, at least in some countries (see box).
A review of the literature on mortality cohort studies 
among problem amphetamines users found that crude 
mortality rates ranged from 0 in Australia to 2.95 per 
100 person-years in Thailand (Singleton et al., 2009). 
Studies carried out in Europe found mortality rates 
ranging from 0.49 in Czech Republic to 2.89 per 100 
person-years in the Netherlands, with studies also 
reported in Sweden and Finland. The Czech cohort 
study included in this review reported an excess 
mortality risk of 6.2 in comparison with non-using 
peers. Only three of the identified studies reported on 
causes of death (102 cases in total), and the majority 
were due to violence, injuries, accidents, and overdoses. 
There was suggestive evidence that injection of 
amphetamines was associated with higher mortality 
than other primary routes of administration. The 
authors of the review concluded that given the 
widespread use of problem amphetamines use, the 
known non-fatal adverse effects of use and the 
mortality rates reported, cohort studies investigating 
the morbidity and mortality associated with such drug 
use should be a research priority. 
A recent large study was conducted among persons 
hospitalised in California for methamphetamine, 
alcohol, opioid, cannabis or cocaine-related disorders 
(Callaghan et al., 2012). The study found that the 
methamphetamine cohort had a higher excess 
mortality risk (4.7 compared with the general 
population), than did users of cocaine, alcohol or 
cannabis, but lower than that of opioid users (5.7). It 
stressed the relative lack of long-term cohort studies of 
mortality risk among individuals with 
methamphetamine-related disorders compared with 
users of other substances. The authors list 
methamphetamine along with cannabis and cocaine as 
drugs lacking long-term mortality cohort studies.
Mortality among amphetamine  
and methamphetamine users
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FIGURE 3
Distribution (%) of the participants by age-band at the time of 
enrolment
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An ageing trend was observed among participants, with age at 
enrolment increasing over time in most cohorts. Norway did 
not follow this pattern and showed a downward trend in age at 
time of enrolment (Figure 4).
The largest contributors to the total number of persons 
enrolled were the cohorts from Barcelona (19 %), Poland 
(15 %) and Latvia (11 %). These cohorts accounted 
respectively for 23 %, 11 % and 13 % of the number of 
person-years followed up. Participants were enrolled and 
followed up from 1994 to 2011, but those who entered at the 
beginning of the last decade make up the bulk of the cohort 
(Figure 5).
FIGURE 4
Mean age (years) of participants at time of enrolment
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NB: For Bucharest, 2007 and 2008 data (two new patients only) are not 
represented in the figure.
FIGURE 5
Numbers of persons enrolling annually in the nine sites of the 
pooled study
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Mortality rates and excess risk
Across the nine studies, 2 886 deaths were recorded, 512 
(18 %) of which were of females. The overall crude mortality 
rate for the pooled cohort, computed with the total number 
of deaths over the 202 947 person-years followed up, was 
14.2 (95 % CI 13.7–14.7) per 1 000 person-years followed up. 
The mortality rates varied from 3.5 per 1 000 person-years in 
Malta to 22.7 per 1 000 person-years in Poland (Table 1).
Caution must be exercised when making comparisons 
between the different studies, as there are differences in the 
time of enrolment, in the coverage (either national or limited to 
a large city), settings, age distribution and characteristics of 
the cohorts. The pooled mortality rate must also be cautiously 
interpreted, bearing in mind the different sizes of the cohorts 
and the variability of their respective mortality estimates. For 
these reasons, some previously published multisite studies 
did not present any pooled results and reported only the 
country estimates (e.g. Bargagli et al., 2006a). A pooled CMR 
is presented here to place the findings in the perspective of 
other pooled results published in the recent literature; it 
should be noted, however, that different methods were used in 
these studies. Mathers et al. (2013) reported a pooled CMR of 
23.5 deaths per 1 000 person-years (95 % CI 21.8–25.8), with 
mortality rates varying across different settings. Degenhardt 
et al. (2011a) reported a pooled all-cause CMR of 21.0 per 
1 000 person-years (95 % CI 19.3–22.6).
The overall standard mortality ratio (SMR) for the pooled 
cohort was 10.0 (95 % CI 9.7–10.4), ranging from 3.5 Malta to 
21.5 Poland (Table 1).
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more likely to be reported for somatic deaths (Clausen et al., 
2009). This raises another caveat, as each death is classified 
by only one cause. This approach may fail to account for the 
complexity of the interlinked causes and determinants of 
deaths. 
Survival
Survival analysis provides an insight into how the risk of death 
accumulates over time (Figure 7). The cohorts in Amsterdam, 
Barcelona, Latvia, Norway and Poland show the lowest 
survival rates, with up to one-tenth of the participants dying 
within the first 5 to 8 years of follow-up, and one-fifth within 
12 to 13 years of follow-up. In contrast, the cohorts in 
Bucharest, Malta, Slovenia and Zagreb showed higher survival 
rates.
In these studies, the mortality risk was quite constant over 
time, within locations, following the enrolment of participants 
in a study. This is in part explained by a sustained level of risk, 
and by the ageing cohort, over the years. With regard to the 
effect of a cohort growing older on the risk of mortality among 
the participants, an initial analysis indicates that the risk 
associated with external causes remains at similar levels for 
the different age bands, but mortality due to somatic causes 
increases with age. 
FIGURE 7
Cumulative survival curves in cohorts of regular or dependent 
opioid users, aged 15 to 64 years old in nine European sites 
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FIGURE 6
Main causes of death among the pooled cohort, where the 
cause of death is reported
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NB: Data for seven of the nine sites, covering 2 043 deaths.
Causes of death
The cause of death was reported for 2 043 (71 %) of all 
deaths. This information was not accessible for the cohorts in 
the Netherlands and Poland, where national regulations on 
data protection do not permit the linkage of the study data 
with the mortality register that is necessary to ascertain the 
cause of death.
Half of the deaths for which the cause was known were due to 
external causes (50 %), mainly overdose, though also 
including suicide, traffic accidents, other accidents and 
homicides (Figure 6). The most frequently reported somatic 
causes of death were HIV/AIDS and diseases of the circulatory 
and respiratory systems. 
Deaths from unknown or ill-defined causes are relatively rare 
in the present pooled study (overall 5 %), compared with some 
cohorts reported in the literature (Degenhardt et al., 2011a; 
EMCDDA, 2011; Ferri et al., 2007; Hickman et al., 2003). In two 
of these studies, however, (Bucharest, 6 %, and Zagreb, 11 %) 
the proportion of ill-defined causes is higher, approaching the 
proportion found in earlier studies, for example in Italy (11 %) 
(Ferri et al., 2007) and in England (12 %) (Schifano et al., 
2005). 
Previous studies have found that the death of an opioid user 
is commonly attributed to several underlying causes. This 
finding points to the ill-health associated with long-term drug 
use and the difficult living conditions experienced by many 
problem opioid users. In particular, multiple causes were 
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(Bargagli et al., 2006a), which was conducted among 
participants enrolled in eight countries during the 1990s. In 
common with the COSMO study, the present exercise found 
that overall mortality rates and excess risk are high, that males 
and older drug users have higher mortality rates compared 
with female and younger drug users, and that overdose 
remains the most common known cause of death among 
opioid users.
Only the cohort studies carried out in Amsterdam and 
Barcelona provided data for both the COSMO study and the 
present study. The present study found that the overall 
mortality rate of the Barcelona cohort (CMR 19.6 per 1 000 
person-years in the period 1997–2007) has halved compared 
with the exceptionally high value found in the COSMO study 
(CMR 37.6 per 1 000 person-years in the period 1992–2001). 
HIV accounted for a large part of overall mortality in the 
COSMO cohorts. During the 1990s, in Spain and in other 
COSMO cohorts in the south-west of Europe, HIV-related 
mortality was high, due to the epidemic of HIV infection 
among injecting drug users. At that time, HIV/AIDS was the 
cause of around one-third or more of deaths among opioid 
users: 38 % in Barcelona, 41 % in Lisbon and 32 % in Rome. 
The decrease in overall mortality observed in the Barcelona 
cohort can be accounted for partly by the decrease in HIV-
related mortality, which fell from 14 deaths per 1 000 person-
years in the COSMO study to 4.45 deaths per 1 000 person-
years in the present study. Also contributing to the decline in 
overall mortality was the decrease in overdose mortality — 
from 13 to 4.9 deaths per 1 000 person-years.
In the Amsterdam cohort, the overall mortality rate reported in 
the present study is unchanged from that found in COSMO 
(CMR 16.4 deaths per 1 000 person-years in 1996–2002; 16.0 
deaths per 1 000 person-years in 1996–2009). This may be 
explained by the smaller impact of antiretroviral treatment, as 
levels of HIV-infection were low in Amsterdam compared with 
Barcelona, and by the lower mortality rate in Amsterdam 
during the first period. With its older age profile, the 
Amsterdam cohort may be expected to witness an increase in 
somatic deaths, related to the long-term consequences of 
previous or current drug use. However, this cannot be verified, 
as information on cause of death is not available for this study.
Apart from Barcelona and Amsterdam, COSMO and the present 
study are based on different sites, which limits comparability. If 
a simple typology can be suggested though, some northern 
European countries of the present analysis (Latvia, Norway and 
Poland) might be grouped. The crude mortality rates per 1 000 
person-years found in these northern cohorts (Latvia, 16.2; 
Norway, 19.2; Poland, 22) were high, and quite similar to the 
mortality rates found in some of the COSMO studies recruited 
10 years earlier (Lisbon, 15.4; Denmark, 17.4; Rome, 20). It can 
I  Public health perspectives  and implications
I Many studies conducted in Europe but gaps remain
Most European countries have now produced some evidence 
from cohort studies on mortality among drug users. The 
present pooled cohort study analysis includes some of the 
most recent data, with some participants followed up to the 
end of 2011. It also provides new insights into drug-related 
mortality in seven countries, mainly located in the eastern half 
of the European Union, that had not participated in COSMO. 
Gaps, however, continue to exist in the information available. 
For some countries, the available data are old, with no recent 
record linkage with mortality registries (e.g. 2003 for Norway 
and 2008 for Barcelona). Some other countries, where 
national figures of drug-induced mortality are high, increasing, 
or both, lack on-going mortality studies (EMCDDA, 2013a; 
EMCDDA, 2013c; Giraudon et al., 2012). That is the case in 
Austria, Finland, Ireland and Sweden, for example. Finally, 
some countries that participated in COSMO (Denmark, Italy, 
Ireland, Portugal) are missing from the present pooled studies. 
I Main findings of the pooled analysis
The pooled analysis is the only European coordinated study on 
mortality among cohorts of problem drug users to be carried 
out in recent years. Mortality rates among drug users 
participating in the study were found to be high, with an 
overall rate of 14 deaths per 1 000 person-years followed up. 
In terms of excess mortality risk, problem drug users were 
typically 10 or more times more likely to die compared with 
their peers in the general population. Mortality rates and 
excess mortality differed widely between countries. 
Pooling data from the different studies enabled a better 
insight into the causes of death, especially from causes that 
are not frequent enough to be discussed in smaller cohorts. 
Overall, half of the deaths for which information was available 
were attributed to external causes, primarily overdose, but 
also including suicide, accidents and violence. The remaining 
deaths were attributed to somatic causes, and related to 
infections (HIV and viral hepatitis), as well as other liver 
diseases and problems of the circulatory and respiratory 
systems. A small proportion of the deaths, 1 in 20, was coded 
with unspecific or ill-defined codes, but this varies between 
countries.
I Comparison with the COSMO multisite study
These findings can be compared, to a certain extent, with 
those of the EMCDDA-coordinated multisite COSMO study 
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be noted that the relatively high overall mortality rates found 
among drug users in some cohorts in the north of Europe 
mirrors to some extent the European geography of reported 
overdose deaths. In 2012, the eight highest national mortality 
rates from drug overdose in Europe were reported by countries 
located in the north — in descending order of mortality rate: 
Estonia, Norway, Ireland, Sweden, Finland, Denmark, the United 
Kingdom and Lithuania (EMCDDA, 2014).
However, the remaining, ‘eastern countries’ of the current 
analysis (Croatia, Malta, Romania and Slovenia) reported 
mortality rates below 10 per 1 000 person-years.
Any attempt to put these findings into perspective must be 
considered with caution, due to differences in recruitment 
settings, time of enrolment and age distribution in particular. 
Nevertheless, the results point to some improvements. One 
example is the reduction in HIV-related mortality observed in 
Barcelona that followed the introduction of antiretroviral 
treatment. The lower mortality rates observed in some of the 
countries in the eastern half of the European Union may 
reflect the later spread and different impact of the heroin 
‘epidemic’ in those countries. In particular, HIV prevalence 
among drug users in these eastern EU Member States is 
much lower than it was in Italy, Portugal and Spain in the 
1990s. Despite a number of the cohorts reporting relatively 
low mortality rates, in half of the countries represented in the 
study, deaths among drug users are at high levels. 
Overdose deaths remain at historically high levels in some of 
the cohorts in the present study. The overdose mortality rate 
in Norway (11.8 deaths per 1 000 person-years) is comparable 
to or higher than the overdose mortality rates in some COSMO 
studies in the 1990s, with death rates per 1 000 person-years 
of 13.0 recorded in Barcelona, followed by London (7.4), 
Denmark (7.1), Rome and Vienna (both 6.6).
In comparison with results collated in a recent systematic 
review and meta-analysis, the mortality rates and excess risk 
found in the nine European cohorts of the current study are 
within the range reported from cohorts in North America, 
central Europe and Australasia, and lower than cohorts in 
Asia or some western European studies published in the 
1990s or the beginning of the 2000s. The review authors 
noted the very high heterogeneity across studies, and 
suggested that study characteristics predict mortality levels 
and should be taken into account in future studies 
(Degenhardt et al., 2011a).
I  Mortality studies: revealing the harms  related to drugs
Mortality data from cohort studies can be used to describe 
the trends in overall levels and causes of death among drug 
users. Data from this source can also provide a 
complementary indicator to assess the burden of mortality 
related to drugs in the European population. In particular, the 
mortality rate related to overdoses observed in the cohorts 
should be consistent with the number of overdoses reported 
in the country’s mortality registries, and with the estimated 
number of problem drug-users. Any inconsistency can point to 
an underestimation by the municipal or national statistics of 
the real number of fatal overdoses occurring and should be 
taken as a signal for the country to audit its recording of 
overdose deaths. This was illustrated by a cohort study 
conducted in Sweden, which estimated that the Swedish 
national causes of death register underestimated drug-related 
deaths by 37 % (Nyhlen et al., 2011).
I Limitations
Comparisons of mortality rates and excess risk are valid only if 
all deaths in a cohort are identified and mortality is not 
underestimated — which may occur, for example, if the data 
linkage misses some deaths. When comparing cause-specific 
mortality rates across countries, it is important to take 
differences in coding of the cause of death into account. In 
addition, the cause of death is not always clearly identified — 
and this varies between countries with the result that large 
‘unknown’ or unspecific categories are evident in some 
studies. Furthermore, for data protection reasons, some 
countries impose limitations on access to data on cause of 
death (e.g. the Netherlands and Poland).
Most cohort studies focus on treatment populations, and it is 
difficult to transfer their results to other more hard-to-reach 
populations of drug users (those not in contact with drug 
treatment). Hard-to-reach drug users should be a priority for 
new studies, as they are likely to be more disadvantaged, at 
higher risk of dying and to warrant priority interventions. 
Information is also lacking about mortality of problem or 
intensive users of drugs other than opioids.
As cohort studies usually consider samples of those in 
treatment, and as treatment, in particular continuous and good 
quality opioid substitution treatment, reduces mortality risk 
(Cornish et al., 2010; Hickman et al., 2011; Kimber et al., 2010), 
the risk observed in these studies may represent a minimum 
estimate of mortality risk for opioid users not in treatment.
Finally, limited work has been carried out in Europe on the 
aetiological fractions of deaths caused by illicit drug use (e.g. 
the proportion of all deaths due to suicide in the population 
that can be attributed to problem drug use). One cause of 
death for which the illicit-drug attributable fraction has been 
estimated for European countries is HIV/AIDS mortality, but 
other causes need to be included, and cohort studies can play 
an important part in this work. 
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substitution treatment, which prevents fatal overdose. In this 
context, morbidity and deaths related to hepatitis, and liver 
disease in general, among older opioid users will become an 
increasing concern. Twenty or more years after becoming 
infected with the hepatitis C virus, these current and former 
drug users face cirrhosis and end-stage liver disease, which 
in some cases is complicated by heavy alcohol use. It is likely 
that the window of follow-up in most cohort studies is not 
long enough to capture the full burden of morbidity and 
death caused by liver diseases (Merrall et al., 2012; Kielland 
et al., 2013a, 2013b).
I  Improving cohort studies and their  usefulness for policymaking
Increased coordination and comparability between the many 
cohort studies that are underway in European countries could 
deliver deeper insights and be of considerable value, both at 
national and European level. Improved cooperation and 
collaboration between treatment services and researchers 
conducting mortality studies may lead to a better 
understanding of the phenomenon.
Gaining a better understanding of drug-related mortality in 
Europe will also require the implementation of cohort studies 
in those Member States that have not yet done so. The 
insights such studies offer into mortality among problem drug 
users and into the effectiveness of interventions require 
relatively little investment. There is no need to set up 
expensive multisite prospective studies, with extensive 
questionnaires and follow-up interviews. At the simplest level, 
all that is required is linkage of data between treatment 
centres and mortality registries, which can be achieved by 
cooperation between the institutions responsible of the 
respective databases — within the scope allowed by national 
regulations on personal data protection. The EMCDDA helps in 
this task by promoting standard methodology (EMCDDA, 
2012), offering technical assistance and by disseminating the 
findings of studies.
I  Conclusion
This exercise provides an updated picture of the ‘old problems’ 
such as HIV-related mortality among problem drug users and 
an insight into new studies. It points to continuing problems 
such as overdose and suicide, and problems that are growing 
in scale as opioid users get older, and as the effects of chronic 
HCV infection in particular and long-term ill-health in general 
are increasingly reflected in mortality statistics. The deaths 
among problem drug users are overwhelmingly premature and 
preventable, especially so for those due to overdose, suicide 
and trauma. 
I  Prevention, treatment and responses:  several priorities
Mortality risk among drug users is heavily influenced by the 
drugs used and how they are consumed, with heroin being the 
drug most strongly associated with elevated mortality risk, 
and injecting the most risky form of administration. Risk of 
death is increased by older age, long-term use of drugs (in 
particular heroin), polydrug use, somatic and psychiatric 
co-morbidity, and not being enrolled in drug treatment 
(Bargagli et al., 2007; Clausen et al., 2008; Cornish et al., 2010; 
Degenhardt et al., 2009). 
Overdoses continue to account for a high share of deaths 
among opioid users, and this can be addressed, as there is 
evidence of good practices to reduce the number of 
overdoses. This was detailed in the Selected Issue (EMCDDA, 
2011), and is not covered in this report. More evidence has 
been collated recently to support prevention, and can be 
briefly referred to though (EMCDDA, 2013e; Frisher et al., 
2012). Frisher et al. report that there are many reasons for 
fatal overdoses and no single measure is likely to have a 
significant impact by itself. Rather, there is evidence that many 
interventions may reduce overdose, particularly in settings 
where the drug user is in contact with treatment or emergency 
services. However, it is important to bear in mind the 
distinction between overdose prevention at the clinical and at 
the population level. At the clinical level, specific interventions 
are available and have been shown to be effective (e.g. 
pharmacological treatment). At the population level, where 
many drug users are not in contact with services, overdose 
reduction depends on behavioural change by drug users 
themselves (e.g. avoiding co-use of opioids and other 
depressant drugs). Overdose prevention is a multifaceted 
problem. Purely technological interventions were thought 
likely to have a relatively limited impact. Rather, overdose 
involves personal and societal issues; only when these are 
addressed is the level of fatal overdose in Europe likely to 
decrease.
Bearing this in mind, particular attention might be given to 
increasing the availability of take-home naloxone (EMCDDA, 
2013c), and to some sub-groups of users who have 
particularly high all-cause and overdose-related mortality risk 
(Hedrich et al., 2012; Lyons et al., 2010; Merrall et al., 2010; 
Zlodre and Fazel, 2012). Deaths due to suicide and trauma 
should be considered as preventable, although these causes 
have received less research attention than overdoses 
(EMCDDA, 2011). 
Finally, somatic causes may represent an increasing share in 
the mortality of older and former opioid users (Beynon et al., 
2010; Stenbacka et al., 2010). In some countries, this is 
related to cohorts of drug users becoming older, and, to 
some extent, the success of well-conducted opioid 
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of cocaine and, to a lesser extent, amphetamine and 
methamphetamine warrants attention, as the numbers using 
these illicit stimulants are an order of magnitude greater than 
the number of opioid users, and some countries report 
increasing levels of use of some of these drugs. Similarly, 
synthetic opioids such as fentanyl have caused ‘outbreaks’ of 
overdoses in recent years (Mounteney et al., 2012), and there is 
increasing concern about deaths related to misuse of 
medicines in some European countries (Giraudon et al., 2013). 
Use of opioids, in particular heroin, continues to account for the 
majority of deaths related to illicit drug use in Europe. Mortality 
cohort studies conducted in many European countries provide 
valuable insights into the harms related to opioids and, in 
particular, heroin. But as patterns of drug use continue to 
change, new studies are needed to monitor the effects and 
impact of these changes on public health. Less evidence is 
available from cohort studies on users of stimulants such as 
cocaine, amphetamine and methamphetamine. Cardiotoxicity 
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I  Cohort study: a type of longitudinal study that follows a group of people (cohort) over time, 
with the purpose of analysing risk factors and identifying events that occur to these people 
(e.g. illness, death). Cohort members may be tracked by re-contacting them or by record 
linkage, which involves checking their status in other databases (e.g. mortality registry).
I  Crude mortality rate: a measure of the number of deaths (in general or due to a specific 
cause) in a population, scaled to the size of that population, per unit time. It is typically 
expressed as either deaths per 100 or 1 000 individuals per year.
I  Drug attributable fraction: the fraction of deaths (overall or due to specific causes) in a 
population to which drug use is the main or a contributing cause (e.g. the proportion of 
HIV/AIDS deaths that is attributable to injecting drug use). 
I  Drug-induced deaths: defined by the EMCDDA as those of ‘people who die directly due to 
use of illegal substances, although these often occur in combination with other 
substances such as alcohol or psychoactive medicines. These deaths generally occur 
shortly after the consumption of the substance.’ These deaths are also known as 
overdoses or poisonings. 
I  Problem drug use: the EMCDDA operationally defines problem drug use as ‘injecting drug 
use or long-duration/regular use of opioids, cocaine and/or amphetamines’. Most cohort 
studies on drug users are conducted among problem drug users, and in particular among 
problem opioid users. The problem drug use EMCDDA key indicator was recently revised, 
and now focuses on a slightly broader concept, high-risk drug use.
I  Standardised mortality rate: a crude mortality rate that has been adjusted for differences 
in age composition between the study population (here, drug users) and a standard 
population. The EMCDDA recommends using the European standard population to 
facilitate comparisons across studies. 
I  Standardised mortality ratio (SMR): a measure of the ‘excess risk of mortality’ of a 
specific group (in this report, drug users), compared with their peers of same age and 
gender in the general population. It is calculated as the observed number of deaths in the 
study, divided by the number of deaths that would be expected, based on the age and 
sex-specific mortality rates in the general population (e.g. an SMR of 15 means that the 
drug users in the study have a 15 times higher mortality than their peers of the same age 
and gender in the general population). The EMCDDA recommends using the European 
standard population as a reference to facilitate comparisons. 
I  Survival analysis: a form of time-to-event analysis in which the event considered is the 
death of participants in the study, and time is measured from the participants’ enrolment 
in the study (e.g. 90 % survival after five years).
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